



2017년 양계 질병 세균 항생제 내성 검사 결과

I Seul Oh
ACE of Optipharm
ois@optipharm.co.kr
043-249-7532

Contents

- I. 항생제 내성/감수성 기준 및 용어 설명
- II. 양계 질병 3종 항생제 내성 검사 결과

1. 항생제 감수성/ 내성 기준

항생제 감수성/ 내성 기준

• 항생제 종류 및 기준(디스크 확산법 기준으로 검역원 자료 참조)

약제명		감수성	효과 중간	내성	약제명	감수성	효과 중간	내성
Ampicillin(AMP10)	Gram -	16	13	6	Gentamicin(CN10)	17	13	6
	Gram +	28	27	6				
Amoxicillin(AML30)		17	13	6	Linsmycin(LS109)	17	13	6
Bacitracin(B10)		12	8	6	Neomycin(N30)	17	13	6
Erythromycin(E30)		23	14	6	Apramycin(APR15)	17	13	6
Tilmicosin(TIL15)		17	14	6	Tiamulin H.Fumarate(Ti25)	17	13	6
Colistin(CT10)		11	9	6	Streptomycin(S10)	15	11	6
Enrofloxacin(ENR5)		22	16	6	Tetracycline(T30)	23	18	6
Florfenicol(FFC25)		18	13	6	Trimethoprim/ Sulfamethoxazole(STX25)	18	15	6
Ceftiofur sodium(C2.5)		17	12	6	Tylosin tartrate(Ty25)	18	13	6

• 항생제 종류 및 기준


Sensitive(감수성)	감수성이 있다는 의미로 치료 효과를 기대할 수 있음.
Resistant(내성)	내성이 있다는 의미로 치료효과 없음.
Intermediate(효과 중간)	감수성과 내성의 중간 정도.

2. 양계 세균성 질병 3종


Salmonella spp.

약 제 명	농장수	검사횟수	항생제 내성, 효과중간, 감수성 비율					
			Resistant		Intermediate		Sensitive	
			검출횟수	%	검출횟수	%	검출횟수	%
Ampicillin(AMP10)	18	40	6	15.0%	3	7.5%	31	77.5%
Amoxicillin(AML30)			5	12.5%	4	10.0%	31	77.5%
Bacitracin(B10)			40	100.0%	0	0.0%	0	0.0%
Erythromycin(E30)			38	95.0%	1	2.5%	1	2.5%
Tilmicosin(TIL15)			31	77.5%	9	22.5%	0	0.0%
Colistin(CT10)			2	5.0%	9	22.5%	29	72.5%
Enrofloxacin(ENR5)			9	22.5%	9	22.5%	22	55.0%
Florfenicol(FFC25)			4	10.0%	5	12.5%	31	77.5%
Ceftiofur sodium(C2.5)			2	5.0%	4	10.0%	34	85.0%
Gentamycin(CN10)			7	17.5%	6	15.0%	27	67.5%
Linsmycin(LS109)			17	42.5%	13	32.5%	10	25.0%
Neomycin(N30)			0	0.0%	7	17.5%	33	82.5%
Apramycin(APR15)			1	2.5%	12	30.0%	27	67.5%
Tiamulin H.Fumarate(Ti25)			36	90.0%	4	10.0%	0	0.0%
Streptomycin(S10)			37	92.5%	2	5.0%	1	2.5%
Tetracycline(T30)			8	20.0%	11	27.5%	21	52.5%
Trimethoprim/ Sulfamethoxazole(STX25)			15	37.5%	8	20.0%	17	42.5%
Tylosin tartrate(Ty25)			40	100.0%	0	0.0%	0	0.0%

Salmonella spp.




Salmonella spp.




Escherichia coli

약제명	농장수	검사횟수	항생제 내성, 효과중간, 감수성 비율					
			Resistant		Intermediate		Sensitive	
			검출횟수	%	검출횟수	%	검출횟수	%
Ampicillin(AMP10)	22	52	17	32.7%	2	3.8%	33	63.5%
Amoxicillin(AML30)			10	19.2%	1	1.9%	41	78.8%
Bacitracin(B10)			47	90.4%	1	1.9%	4	7.7%
Erythromycin(E30)			48	92.3%	0	0.0%	4	7.7%
Tilmicosin(TIL15)			45	86.5%	7	13.5%	0	0.0%
Colistin(CT10)			0	0.0%	0	0.0%	52	100.0%
Enrofloxacin(ENR5)			21	40.4%	14	26.9%	17	32.7%
Florphenicol(FFC25)			15	28.8%	6	11.5%	31	59.6%
Ceftiofur sodium(C2.5)			7	13.5%	0	0.0%	45	86.5%
Gentamycin(CN10)			9	17.3%	13	25.0%	30	57.7%
Linsmycin(LS109)			9	17.3%	12	23.1%	31	59.6%
Neomycin(N30)			6	11.5%	27	51.9%	19	36.5%
Apramycin(APR15)			19	36.5%	31	59.6%	2	3.8%
Tiamulin H.Fumarate(Ti25)			33	63.5%	17	32.7%	2	3.8%
Streptomycin(S10)			30	57.7%	16	30.8%	6	11.5%
Tetracycline(T30)			34	65.4%	14	26.9%	4	7.7%
Trimethoprim/ Sulfamethoxazole(STX25)			15	28.8%	3	5.8%	34	65.4%
Tylosin tartrate(Ty25)			52	100.0%	0	0.0%	0	0.0%

Escherichia coli




Escherichia coli



Clostridium perfringens

약제명	농장수	검사횟수	항생제 내성, 효과중간, 감수성 비율					
			Resistant		Intermediate		Sensitive	
			검출횟수	%	검출횟수	%	검출횟수	%
Ampicillin(AMP10)	4	5	3	60.0%	0	0.0%	2	40.0%
Amoxicillin(AML30)			0	0.0%	0	0.0%	5	100.0%
Bacitracin(B10)			3	60.0%	0	0.0%	2	40.0%
Erythromycin(E30)			4	80.0%	1	20.0%	0	0.0%
Tilmicosin(TIL15)			4	80.0%	0	0.0%	1	20.0%
Colistin(CT10)			4	80.0%	0	0.0%	1	20.0%
Enrofloxacin(ENR5)			2	40.0%	0	0.0%	3	60.0%
Florphenicol(FFC25)			0	0.0%	0	0.0%	5	100.0%
Ceftiofur sodium(C2.5)			0	0.0%	0	0.0%	5	100.0%
Gentamycin(CN10)			4	80.0%	1	20.0%	0	0.0%
Linsmycin(LS109)			1	20.0%	4	80.0%	0	0.0%
Neomycin(N30)			4	80.0%	1	20.0%	0	0.0%
Apramycin(APR15)			4	80.0%	1	20.0%	0	0.0%
Tiamulin H.Fumarate(Ti25)			1	20.0%	0	0.0%	4	80.0%
Streptomycin(S10)			5	100.0%	0	0.0%	0	0.0%
Tetracycline(T30)			3	60.0%	1	20.0%	1	20.0%
Trimethoprim/ Sulfamethoxazole(STX25)			3	60.0%	1	20.0%	1	20.0%
Tylosin tartrate(Ty25)			1	20.0%	0	0.0%	4	80.0%

Clostridium perfringens



Clostridium perfringens

